[go: up one dir, main page]

CN1022248C - Novel 2'-halomethylidene, uridine and guanosine drivatives - Google Patents

Novel 2'-halomethylidene, uridine and guanosine drivatives Download PDF

Info

Publication number
CN1022248C
CN1022248C CN89108557A CN89108557A CN1022248C CN 1022248 C CN1022248 C CN 1022248C CN 89108557 A CN89108557 A CN 89108557A CN 89108557 A CN89108557 A CN 89108557A CN 1022248 C CN1022248 C CN 1022248C
Authority
CN
China
Prior art keywords
compound
deoxidation
methylene
ethynyl
pyrimidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN89108557A
Other languages
Chinese (zh)
Other versions
CN1042715A (en
Inventor
麦卡锡·杰姆斯·雷
埃德华兹·米克尔·路易斯
麦特休斯·唐纳德·保尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of CN1042715A publication Critical patent/CN1042715A/en
Application granted granted Critical
Publication of CN1022248C publication Critical patent/CN1022248C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

This invention relates to certain novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives, and compositions thereof, which are useful in the treatment of patients afflicted with neoplastic or viral disease states.

Description

Novel 2'-halomethylidene, uridine and guanosine drivatives
The present invention relates to new 2 '-halogenated methylene, 2 '-vinylidene and 2 '-ethynyl born of the same parents (pyrimidine nuclear) glycosides, urine (pyrimidine nuclear) glycosides and bird (purine nuclear) glycoside derivates can be used as antiviral and antineoplastic agent.
The invention provides the formula I new 2 '-the halogenated methylene derivative
Figure 891085572_IMG3
（1）
Wherein
V is an oxygen, methylene radical or sulphur,
X 1And X 2Represent hydrogen or halogen independently,
Condition is X at least 1And X 2One of be halogen,
B is the following formula group
Y wherein 1Be nitrogen, CH base, CCl base, CBr base or CNH 2Base; Y 2And Y 3Represent nitrogen or CH base independently; Y 4Be hydrogen, C 1-C 4Alkyl, C 1-C 4Alkoxy or halogen; Y 5Be amino or C 1-C 4Alkoxyl group; And Z is a hydrogen, halogen or NH 2;
Or its pharmaceutical salts.
In addition, the present invention also propose formula (1a) new 2 '-the vinylidene derivative
Figure 891085572_IMG5
（1a）
Wherein
R is hydrogen or C 1-C 4Alkyl,
And V and B such as above-mentioned;
Or its pharmaceutical salts.
And, the present invention also propose formula (1b) new 2 '-ethynyl derivatives serving
Figure 891085572_IMG6
（1b）
A wherein 1And A 2Represent independently hydrogen or-C ≡ CR base,
Condition is A 1During for hydrogen, A 2For-C ≡ CR base, and A 1For-when C ≡ CR is basic, A 2Be hydrogen, and V, R and B such as above-mentioned;
Or its pharmaceutical salts.
The present invention also propose formula (6) new 2 '-the aryl sulfonyl methylene derivatives
Figure 891085572_IMG7
（6）
Wherein Ar is C 6-C 12Aryl, X MALBe halogen, and V and B such as above-mentioned.Formula (6) compound can be used as X in the synthesis type (1) 1Or X 2One of the middle chemical product when being the compound of hydrogen.
Another embodiment of the present invention is the method that proposes treatment tumour patient or control patient tumor growth in vivo, comprising taking effective therapeutic dose formula (1), (1a) or antineoplastic compound (1b).
Another embodiment of the present invention is to propose the method that treatment virus infection patient or control patient body inner virus infect, comprising taking effective therapeutic dose formula (1), (1a) or antiviral compound (1b).
Here used " halogen " or " halo " refer to fluorine, chlorine, and the bromine or iodine atom, and " nitrogen " refers to be connected with the trivalent nitrogen atom of two groups." C 1-C 4" alkyl refers to 1～4 carbon saturated straight chain or branched hydrocarbyl, comprises methyl, ethyl, propyl group, sec.-propyl, normal-butyl, isobutyl-, the tertiary butyl etc.
Used " C 6-C 12Aryl " refer to about 6 to about 12 carbon aromatic hydrocarbons, as phenyl, naphthyl or phenyl (C 1-C 4) alkyl, wherein said group can be selected from C by 1,2 or 3 in case of necessity 1-C 4Alkyl, halo C 1-C 4Alkyl, halogen or C 1-C 4The substituting group of alkoxyl group replaces.Used " phenyl (C 1-C 4) alkyl " refer to use C 1-C 4The phenyl that alkyl replaces comprises phenmethyl and styroyl.Used " halo C 1-C 4Alkyl " refer to the C that 1～3 halogen atom that comprises fluorine and chlorine replaces 1-C 4Alkyl.Used " C 1-C 4Alkoxyl group " refer to C with the oxygen base 1-C 4Alkyl comprises methoxyl group, oxyethyl group, propoxy-, butoxy etc.
Formula (1), (1a) and (1b) 2 '-halogenated methylene, 2 '-vinylidene and 2 '-ethynyl derivatives serving can make with common technological process known to those skilled in the art.
X in the formula (1) 1And X 2The compound method for making that is halogen has seen down shows flow process A, and wherein unless otherwise indicated and outer, all substituting groups are all as above-mentioned.In addition, used " φ " refers to phenyl; Used " X HALRefer to halogen atom; Used " LP=" refers to that [for example, difluoro methylene phosphine inner salt-type is (φ) to phosphorus inner salt residue 2P(O)=C(F) 2, be abbreviated as LP=C(F) 2].
Among the step a, ketone derivatives (2), as 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-ketone-glycosyl]-2-(1H)-pyrimidone can be in the reaction of Wittig class with dihalo methylene radical phosphorus in reactant salt get the derivative (3) that corresponding 2-dihalo methylene radical replaces, as 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-difluoro methylene-glycosyl]-2(1H)-pyrimidone.
The phosphorus inner salt can make by the known method of specialty chemical, as seeing J.March, " Advanced Organic Chemistry:Reactions, Mechanisms and Strucure ", Mc Graw-Hill Book Com-pany, 702-10(1968).For example, the phosphorus inner salt can be handled suitable phosphorane or phosphate derivatives with appropriate base and get.Can adopt a large amount of alkali, comprise alkoxide and organometallic compound, as lithium alkylide or lithium dialkyl amide.X in the preparation formula I 1And X 2When being the compound of halogen, among the step a available dihalo methylene radical phosphorus inner salt.
Suitable phosphorane or phosphonic acid ester can be with phosphine or phosphine oxides, and as trialkyl phosphine, triaryl phosphine (comprising triphenylphosphine) and diaryl phosphine oxide (comprising diphenyl phosphine oxide) add suitable two or three methyl halide derivatives and make.Can convert it into corresponding phosphorus inner salt with alkaline purification phosphorane or phosphonic acid ester.This can produce phosphorane or phosphonic acid ester and finish in the presence of suitable alkali.X in the requirement formula (1) 1And X 2When being the compound of halogen, father-in-law's reactant salt in suitable ketone (2) and the dihalo methylene radical phosphorus can get, the latter reacts with three methyl halides phosphine or phosphine oxide and forms under alkali exists.
More particularly, when requiring X 1And X 2When being the compound of fluorine, with suitable ketone
Flow process A
(2) with two fluoro methylene radical phosphorus in father-in-law's reactant salt, the latter reacts phosphine or phosphine oxide (as diphenyl phosphine oxide) and difluoro methyl halide (as difluorochloromethane) and gets in the presence of alkali (as butyllithium).
Among the step b, the technology that the tetra isopropyl disiloxane protecting group of formula (3) is known with common methods and this specialty is removed and is promptly got deprotection base dihalo methylene derivatives (4).(3) and fluorine anion or acid-respons can be sloughed the tetra isopropyl disiloxane protecting group effectively, can not make again simultaneously to require the product degraded.For example, available tetrabutyl ammonium fluoride, dilute acetic acid or dilute hydrochloric acid.
At the pyrimidone that adopts the 4-alkoxyl group to replace, the pyrimidone that replaces as the 4-oxyethyl group is during as the initial material (2) of step a, just can in step b, the 4-alkoxyl group in the pyrimidone alkali be changed into the 4-ketone group, thereby make corresponding uridine or chest (gland pyrimi piperidine deoxidating nucleus) glycosides (4) or change into 4-amino, thereby make corresponding cytidine derivatives (4).These reactions can be undertaken by the technology that specialty chemical is known.For example, when requiring uridine or thymidine derivative, the 4-oxyethyl group-dihalo methylene derivatives of formula (4) is used alkali again, in nucleophilic displacement/enolization reaction the 4-oxyethyl group is changed into the 4-ketone group as sodium-hydroxide treatment.When requiring cytidine derivatives, the 4-oxyethyl group-dihalo methylene derivatives of formula (4) makes NH with the methanol ammonia reaction again 2Base replaces the 4-oxyethyl group.
The typical synthetic method of following example table free flow journey A.Should be understood that these examples only for illustrative, do not limit protection scope of the present invention.
Example 1
2 '-deoxidation-2 '-the difluoro methylene cytidine
Step a:
4-oxyethyl group-1-[3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-(difluoro methylene) and glycosyl]-2(1H)-pyrimidone
Produce phenylbenzene difluoromethyl phosphine oxide as follows:
(25gm 124mmol) is being cooled in-50 ℃ the solution of tetrahydrofuran (THF) (THF) in (600ml) and adds the hexane solution of 70ml 1.8M n-Butyl Lithium and keep 20min in-50 ℃ to diphenyl phosphine oxide.Slowly drip excessive difluorochloromethane and stir 3h down in-50 ℃.Mixture reaches the room temperature final vacuum and steams solvent.Once more residuum is dissolved in chloroform/water (1/1, v/v; 200ml).Tell organic layer, use anhydrous magnesium sulfate drying, and be evaporated to dried.Fast silica gel chromatogram is purified, wherein use toluene/ethyl acetate (1/1, v/v) wash-out.The phenylbenzene difluoromethyl phosphine oxide of must purifying (93～94 ℃ of fusing points) with the hexanes/ch recrystallization again.
Diisopropylamine (1.7ml, THF(24ml 12mmol)) solution is cooled to-20 ℃ in chloroform/the dry ice bath.Drip the n-Butyl Lithium (the 1.35mol hexane solution of 8.88ml) and the 20min that stirs the mixture.In acetone/the dry ice bath, mixture is cooled to-70 ℃.Be added dropwise to phenylbenzene difluoromethyl phosphine oxide (3.02g, THF(12ml 12mmol)) solution, its feed rate should guarantee that mixture temperature is not higher than-65 ℃.Mixture is added dropwise to 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases after stirring 30min)-red-penta furyl glycosyl of 2-ketone-β-D-]-2(1H)-pyrimidone (5.12gm, THF(20ml 10mmol)) solution.Under-70 ℃ mixture is stirred 1h, 1/2h gradually refluxes mixture heating up after the room temperature.Again mixture is cooled to room temperature, adds ethyl acetate (500ml) and use saturated sodium bicarbonate aqueous solution (100ml) purging compound.Tell organic layer, use anhydrous magnesium sulfate drying, and vacuum-evaporation is to doing.Fast silica gel chromatogram purification residuum, wherein use ethyl acetate/hexane (1/1, v/v) make elutriant, show compound thereby make topic.
Step b:
2 '-deoxidation-2 '-the difluoro methylene cytidine
To the THF(2.2ml of 1.0M tetrabutyl ammonium fluoride, (546mg 1mmol) and under room temperature stirs 2h with mixture to the compound that makes in 2.2mmol) adding a) in the solution.Use the acetate neutralise mixt, in mixture, add quick silica gel and vacuum-evaporation to doing.Fast silica gel chromatogram purification residuum, wherein use chloroform/ethanol (9/1, v/v) wash-out, thereby make 4-oxyethyl group-1-[β-D-red-penta furans-2-(difluoro methylene) glycosyl]-2(1H)-pyrimidone.
This compound that will just make in the sealed tube (909g, 100 ℃ of heating of methanol ammonia 3mmol) (10ml, 0 ℃ saturated) solution 2 days.Solution evaporation must be inscribed and show compound to doing.
Can make following compound with the method that is similar to example 1:
2 '-deoxidation-2 '-difluoro methylene-5-methylcytidine
2 '-deoxidation-2 '-difluoro methylene-5-methylol cytidine
2 '-deoxidation-2 '-dichloro methylene radical cytidine
2 '-deoxidation-2 '-difluoro methylene-4 '-the sulfo-cytidine
(±) (1 β, 3 α, 4 β)-1-(4-amino-2-hydroxy pyrimidine-6-yl)-2-difluoro methylene-3-hydroxy-4-hydroxymethyl methylcyclopentane.
Embodiment 2
2 '-deoxidation-2 '-the difluoro methylene uridine
Step a:
4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-(difluoro methylene) and glycosyl)-2-(1H)-pyrimidone
Topic shows that the compound method for making is with step a in the example 1.
Step b:
2 '-deoxidation-2 '-the difluoro methylene uridine
4-oxyethyl group-1-[β-D-is red-penta furans-2-(difluoro methylene) and glycosyl]-2(1H)-the pyrimidone method for making is with step b in the example 1.
After stirring 23h under the compound (608mg, THF(15ml 2mmol)) that makes like this and 1N sodium hydroxide (5ml) the solution room temperature, stir 2h in 60 ℃.Use Amber-lite IRC-50(H again +-Shi) leach resin behind the neutralization reaction liquid.Evaporated filtrate must be pointed out compound to doing.
Can make following compound with the method that is similar to example 2:
2 '-deoxidation-2 '-the difluoro methylene thymidine
2 '-deoxidation-2 '-difluoro methylene-5-hydroxymethyluridine
2 '-deoxidation-2 '-dichloro methylene radical uridine
2 '-deoxidation-2 '-difluoro methylene-4 '-thio uridine
(±)-(1 β, 3 α, 4 β)-1-(2,4-dihydroxy-pyrimidine-6-yl)-2-difluoro methylene-3-hydroxy-4-hydroxymethyl methylcyclopentane.
Example 3
2 '-deoxidation-2 '-the difluoro methylene guanosine
Step a:
1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-(difluoro methylene) and glycosyl] guanine
Topic shows that compound is to be same as the method 1-[(3 of step a in the example 1,5-O-tetra isopropyl disiloxane-1,3-two bases)-red-penta furyl glycosyl of 2-ketone-β-D-] (5.16g 10mmol) makes guanine.
Step b:
2 '-deoxidation-2 '-the difluoro methylene guanosine
Topic shows that compound is to be same as the method 9-[(3 of step b in the example 1,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-(difluoro methylene) and glycosyl] (0.55g 1mmol) makes guanine.
Can make following compound with the method that is similar to example 3:
2 '-deoxidation-2 '-dichloro methylene radical guanosine
2 '-deoxidation-2 '-difluoro methylene-4 '-the sulfo-guanosine
X in the formula (1) 1And X 2One of see flow process B for the general synthesis method of the compound of hydrogen.
Flow process B
Among the step a, with ketone derivatives (2), as 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-ketone-glycosyl]-2(1H)-the phosphorus inner salt of making general remark among pyrimidone and the flow process A reacts in the reaction of Wittig class.Requiring X 1And X 2One of when being the compound of hydrogen, (2) can be with reactant salt in the aryl sulfonyl halogenated methylene phosphorus corresponding 2-aryl sulfonyl halogenated methylene derivative (5), as 2-phenyl sulfonyl halogenated methylene derivative.
Suitable aryl sulfonyl halogenated methylene phosphorus inner salt can make with the method that specialty chemical is known.For example, X in requiring formula (1) 1And X 2One of when being the compound of hydrogen, can be with reactant salt in the ketone that suits (2) and the aryl sulfonyl halogenated methylene phosphorus, the latter reacts halogenated phosphate (diethyl chlorine phosphoric acid ester) and halogenated methyl aryl sulfone under alkali (as the lithium diisopropylamide) and gets.
More particularly, X in requiring formula (1) 1And X 2In one of be fluorine another during for the compound of hydrogen; the interior reactant salt of suitable ketone (2) and aryl sulfonyl fluoro methylene radical phosphorus can be got, and the latter reacts halo acid esters (as diethyl chlorine phosphoric acid ester) and fluoro methyl aryl sulfone and gets in the presence of alkali (as the lithium diisopropylamide).
Among the step b, the tetra isopropyl disiloxane protecting group in (5) removes as flow process A(step b), thereby makes the derivative (6) that corresponding deprotection base 2-aryl sulfonyl halogenated methylene replaces.For example, available fluoride salt removes the tetra isopropyl disiloxane protecting group as tetrabutyl ammonium fluoride.
Among the step c, the aryl sulfonyl in (6) removes and makes corresponding 2-halogenated methylene derivative (7) with the hydrogen atom replacement.The method that this available specialty chemical is known is finished, as with (6) and aluminium/amalgam or sodium/amalgam or the two isobutyl-nitriles (AIBN) of tri-butyl tin hydride/azo reacts in backflow benzene after the acidic aqueous solution processing.
The derivative (6) that 2-aryl sulfonyl halogenated methylene replaces is a new compound, can be used as X in the formula (1) 1Or X 2One of be the compound of the hydrogen intermediate chemicals when synthetic.Symbol " Ar " refers to as above-mentioned C in formula (6) compound 6-C 12Aryl.Ar is a phenyl in formula (6) preferred compound.
At the pyrimidone that adopts the 4-alkoxyl group to replace, the pyrimidone that replaces as the 4-oxyethyl group is during as the initial material (2) of step a, can in step c, 4-alkoxyl group in the pyrimidone alkali be changed into the 4-ketone group, thereby make corresponding uridine or thymidine derivative (7) and maybe can change into 4-amino, thereby make corresponding cytidine derivatives (7).These reactions can be finished by the method that specialty chemical described in the flow process A is known.
Know as those skilled in the art, 2 of compound among the flow process B (7) representative '-the halogenated methylene derivative exists with two kinds of geometrical isomers, can be described as (Z) and (E) isomer.These isomer can be separated with the known conventional isolation technique of this specialty.For example, adopt Dowex 1-X2(OH -Resin column chromatography cartesian geometry isomer likes).
The typical synthetic method of following example table free flow journey B.Should be understood that these examples only for illustrative, do not limit protection scope of the present invention.
Example 4
(Z) and (E)-2 '-deoxidation-2 '-fluoro methylene radical cytidine
Step a:
4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-(2-fluoro-2-phenyl sulfonyl methylene radical) and glycosyl]-2(1H)-pyrimidone
Produce diethyl fluoro aminomethyl phenyl alkylsulfonyl phosphonic acid ester as follows:
To fluoro methyl phenyl sulfone (500mg, 2.87mmol) be cooled to approximately-60 ℃ THF(30ml) and in make solution, cooling is in the band stirring rod, the argon gas inlet valve, carry out in the anhydrous flask of 100ml three necks of thermometer and diaphragm of rubber, then with syringe add diethyl chloro phosphoric acid ester (500mg, 0.42ml, 2.87mmol).The hexanaphthene (3.48ml, 5.74mmol) solution and confirm to have formed diethyl fluoro aminomethyl phenyl alkylsulfonyl phosphonic acid ester that in this mixture, add 1.65M lithium diisopropylamide afterwards again with syringe through the vapour-liquid chromatogram.
In above-claimed cpd, add 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-red-penta furyl glycosyl of 2-ketone-β-D-]-2-(1H)-pyrimidone (732mg, the about 5ml of anhydrous THF(2mmol)) solution and reaction mixture is spent the night be raised to room temperature.This mixture is poured in the saturated ice-cooled ammonium chloride solution also with ethyl acetate extraction mixture (3 times, each 75ml).Organic phase is integrated, use anhydrous magnesium sulfate drying, and be evaporated to dried.With quick silica gel column chromatography purification residuum, wherein use ethyl acetate/hexane (1/1, v/v), show compound thereby obtain topic.
Step b:
4-oxyethyl group-1-[β-D-is red-penta furans-2-(2-fluoro-2-phenyl sulfonyl methylene radical) and glycosyl]-2(1H)-pyrimidone
To the THF(2.2ml of 1.0M tetrabutyl ammonium fluoride, (668mg 1mmol) and under room temperature stirs 2h with mixture 2.2mmol) to add the compound of gained among the step a in the solution.Use the acetate neutralise mixt, quick silica gel adding mixture and vacuum-evaporation are extremely done.With quick silicagel column purification residuum, wherein use chloroform/ethanol (20/1, v/v), show compound thereby obtain topic.
Step c:
(Z)-and (E)-2 '-deoxidation-2 '-fluoro methylene radical cytidine
Under the nitrogen atmosphere in step b the gained compound (854mg adds aluminium amalgam (by 0.04gm aluminium at 2%Hg Cl in the 10%THF aqueous solution (100ml) solution 2mmol) 2Make in the aqueous solution).Stir also and ventilate in mixture simultaneously, 2h simultaneously refluxes.Mixture filters and the most of THF of vacuum-evaporation.With ethyl acetate extraction mixture (3 times, each 25ml), organic layer integrates and uses anhydrous Na 2SO 4Dry.Vacuum-evaporation to dry doubling is purified with quick silica gel, wherein use chloroform/ethanol (9/1, v/v) wash-out, thus (Z) that obtain existing-and (E)-4-oxyethyl group-1-[β-D-with the geometrical isomer mixture red-penta furans-2-(2-fluorine methylene radical) glycosyl]-2(1H)-pyrimidone.
(858mg, methanol ammonia 3mmol) (10ml, 0 ℃ saturated) solution heated 2 days for 100 ℃ with above-claimed cpd in sealed tube.Solution evaporation to dry doubling Dowex 1-X2(OH -Packed column and methyl alcohol are made the chromatographic purification residuum of elutriant and are told (Z) and (E) isomer of prompting compound likes).
Can make following compound with the method that is similar to example 4:
(E) and (Z)-2 '-deoxidation-2 '-fluoro methylene radical-5-methylcytidine
(E) and (Z)-2 '-deoxidation-2 '-fluoro methylene radical-5-methylol cytidine
(E) and (Z)-2 '-deoxidation-2 '-fluoro methylene radical cytidine
(E) and (Z)-2 '-deoxidation-2 '-fluoro methylene radical-4 '-the sulfo-cytidine
(±)-(1 β, 3 α, 4 β)-1-(4-amino-2-hydroxy pyrimidine-6-yl)-2(E and Z)-fluoro methylene radical-3-hydroxy-4-hydroxymethyl methylcyclopentane
Example 5
(Z)-and (E)-2 '-deoxidation-2 '-fluoro methylene radical uridine
Step a:
4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-(2-fluoro-2-phenyl sulfonyl methylene radical) and glycosyl]-2(1H)-pyrimidone
Topic shows that the compound method for making is same as step a in the example 4.
Step b:
4-oxyethyl group-1-[β-D-is red-penta furans-2-(2-fluoro-2-phenyl sulfonyl methylene radical) and glycosyl]-2(1H)-pyrimidone
Topic shows that the compound method for making is same as step b in the example 4.
Step c:
(Z)-and (E)-2 '-deoxidation-2 '-fluoro methylene radical uridine
4-oxyethyl group-1-[β-D-is red-penta furans-2-(2-fluoro methylene radical) and glycosyl]-2(1H)-the pyrimidone method for making is same as step c in the example 4.
The compound that to make like this under the room temperature (572mg, THF(15ml 2mmol)) and 1N sodium hydroxide (5ml) solution stirring 23h also stir 2h in 60 ℃.Use Amberlite IRC-50(H +-Shi) neutralization reaction liquid and leach resin.Filtrate is evaporated to dried and must inscribes and show compound.Residuum Dowex 1-X2(OH -Packed column and make elutriant and divide to set a question and show (Z) of compound and (E) isomer with 0.1M bicarbonate of ammonia likes).
Can be made into following compound with the method that is similar to example 5:
(E) and (Z)-2 '-deoxidation-2 '-fluoro methylene radical-5-hydroxymethyluridine
(E) and (Z)-2 '-deoxidation-2 '-fluoro methylene radical thymidine
(E) and (Z)-2 '-deoxidation-2 '-chloro methylene radical uridine
(E) and (Z)-2 '-deoxidation-2 '-fluoro methylene radical-4 '-thio uridine.
Example 6
(Z)-and (E)-2 '-deoxidation-2 '-fluoro methylene radical guanosine
Step a:
9-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-(2-fluoro-2-phenyl sulfonyl methylene radical) and glycosyl] guanine
Topic shows that compound is to be same as the method 9-[(3 of step a in the example 4,5-O-tetra isopropyl disiloxane-1,3-two bases)-red-penta furyl glycosyl of β-D-] guanine makes.
Step b:
9-[β-D-is red-penta furans-2-(2-fluoro-2-phenyl sulfonyl methylene radical) and glycosyl] guanine
Topic shows that compound makes with step a gained compound with the method that is used for example 4 step b.
Step c:
(Z)-and (E)-2 '-deoxidation-2 '-fluoro methylene radical guanosine
Topic shows that compound makes with step b gained compound with the method that is same as step c in the example 4.
Also can make following compound with the method that is similar to example 6:
(Z)-and (E)-2 '-deoxidation-2 '-chloro methylene radical guanosine
(Z)-and (E)-2 '-deoxidation-2 '-fluoro methylene radical-4 '-the sulfo-guanosine
(±)-(1 β, 3 α, 4 β)-1-(2-amino-6-hydroxyl-9H-purine-9-yl)-2(E and Z)-fluoro methylene radical-3-hydroxy-4-hydroxymethyl methylcyclopentane
The general synthesis method of formula (1a) compound sees flow process C, and it is the compound of hydrogen that this flow process is specially adapted to the middle R of the formula of producing (1a).
Flow process C
Among the step a, ketone derivatives (2), as 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-ketone-glycosyl]-2(1H)-pyrimidone and acetylenic Grignard reagent, reagent react shown in general formula R C ≡ CMg Br and corresponding 2-alkynyl alcohol (8).On the other hand, alcohol (8) available again other organometallic compound that obtains from reactive metal, compound shown in general formula R C ≡ CLi and making.
Suitable Grignard reagent, or other organometallic reagent can be by the known method of specialty chemical, as seeing J.March at " Advanced Organic Chemistry:Reactions; Mechanisms and Structure ", Mc Graw-Hill Book Company, 684-88 and 697-98(1968) described in method make.For example, the Grignard reagent of the acetylene that replaces of acetylene or alkyl can be handled the acetylene of acetylene or alkyl replacement and gets with the methyl magnesium bromide under anhydrous condition.
Certainly, those skilled in the art are known, and 2-acetylene alcohol (8) one of can diastereomer exists, as ethynyl in one of them in the furanose basic ring with 3-hydroxyl the same side, and among another ethynyl in the furanose basic ring with purine or pyrimidyl the same side.Adopting 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-and β-D-is red-penta furans-2-ketone-glycosyl]-2-(1H)-when pyrimidone is made initial material (2), these diastereomers are called 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-and β-D-ribose-penta furans-2(ethynyl) glycosyl]-2(1H)-pyrimidone and 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-arabinose-penta furans-2-(ethynyl) glycosyl]-2(1H)-pyrimidone.
Among the step b, 2-ethynyl alcohol (8) is reduced into 2-vinylidene derivative (9).This reduction can be by the known method of specialty chemical, as handling 2-ethynyl alcohol with lithium aluminium hydride and aluminum chloride and finishing.
Among the step c, the tetra isopropyl disiloxane protecting group in (9) is removed by flow process A(step b), thereby makes corresponding deprotection base 2-vinylidene derivative (1a).
At the pyrimidone that adopts the 4-alkoxyl group to replace, the pyrimidone that replaces as the 4-oxyethyl group is during as the initial material (2) of step a, the 4-alkoxyl group can change into the 4-ketone group in the pyrimidone alkali, thereby make corresponding uridine or thymidine derivative (1a) and maybe can change into 4-amino, thereby make corresponding cytidine derivatives (1a).But these reaction specialty chemicals are known and are undertaken by the described method of flow process A.
Following example has illustrated the described typical synthetic method of flow process C.Should be understood that these examples only for illustrative, and limit protection scope of the present invention never in any form.
Example 7
2 '-deoxidation-2 '-the vinylidene cytidine
Step a:
4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-(ribose-or arabinose-) penta furans-2-(ethynyl) glycosyl] 2(1H)-pyrimidone
Under 0 ℃, with the saturated THF(750ml of acetylene) and (51ml 0.1mol), still rouses the acetylene bubble simultaneously in solution to be added dropwise to 1.95N methyl magnesium bromide.20min stops the acetylene air-flow and uses argon purge 20min after the methylate magnesium bromide.In this solution, add 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-and β-D-is red-penta furans-2-ketone-glycosyl]-2(1H)-and pyrimidone (2.73g, THF(20ml 5mmol)) solution, make reaction mixture heat after room temperature, stir 16h.Add the 1600ml ethyl acetate and use saturated NH 4The Cl aqueous solution (200ml) purging compound.Extremely do with anhydrous magnesium sulfate drying organic layer and vacuum-evaporation.Residuum is purified with quick silica gel column chromatography, wherein use ethyl acetate/hexane (1/1, v/v) make elutriant, show compound thereby make topic.
Step b:
4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two)-β-D-is red-penta furans-2-(vinylidene) and glycosyl]-2(1H)-pyrimidone
To lithium aluminium hydride (76mg, 2mmol) and aluminum chloride (132mg, 1mmol) in being cooled to 0 ℃ the stirred solution of anhydrous diethyl ether (4ml) lining, be added dropwise to 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-(ribose-or arabinose-) penta furans-2-(ethynyl) glycosyl]-2(1H)-pyrimidone (531mg, anhydrous diethyl ether 1mmol) (2ml) solution.Adding 10% sal enixum (10ml) behind the stirred reaction mixture 1h gets off the reaction quenching.With ethyl acetate wash water solution (3 times, each 20ml).Organic layer integrates, and uses anhydrous magnesium sulfate drying, and vacuum concentration.Residuum is purified with quick silica gel column chromatography, wherein with ethyl acetate/hexane do elutriant (1/1, v/v), show compound thereby make topic.
Step c:
2 '-deoxidation-2 '-the ethylidene cytidine
To the THF(2.2ml of 1.0M tetrabutyl aluminium fluoride, 2.2mmol) add in the solution a) in the gained compound (513mg, 1mmol) and the 2h that under room temperature, stirs the mixture.Use the acetate neutralise mixt, in mixture, add quick silica gel and vacuum-evaporation to doing.Residuum is purified with quick silica gel column chromatography, wherein use chloroform/ethanol (20/1, v/v), thereby make 4-oxyethyl group-1-[β-D-red-penta furans-2-(vinylidene) glycosyl]-2(1H)-pyrimidone.
With (840mg, methanol ammonia 3mmol) (10ml, 0 ℃ saturated) the solution 100 ℃ of heating 2 days in sealed tube of the compound that makes like this.Solution evaporation must be inscribed and show compound to doing.
Also can make following compound with the method that is similar to example 3:
2 '-deoxidation-2 '-vinylidene-5-methylcytidine
2 '-deoxidation-2 '-vinylidene-5-methylol cytidine
2 '-deoxidation-2 '-vinylidene-4 '-the sulfo-cytidine
(±)-(1 β, 3 α, 4 β)-1-(4-amino-2-hydroxy pyrimidine-6-yl)-2-vinylidene-3-hydroxy-4-hydroxymethyl methylcyclopentane.
Example 8
2 '-deoxidation-2 '-the vinylidene uridine
Step a:
4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β, D-(ribose-or arabinose-) penta furans-2-(ethynyl) glycosyl]-2(1H)-pyrimidone
Topic shows that the compound method for making is same as step a in the example 7.
Step b:
4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-(vinylidene) and glycosyl]-2(1H)-pyrimidone
Topic shows that the compound method for making is same as step b in the example 7.
Step c:
2 '-deoxidation-2 '-the vinylidene uridine
4-oxyethyl group-1-[β-D-is red-penta furans-2-(vinylidene) and glycosyl]-2(1H)-the pyrimidone method for making is same as step c in the example 7.
Stir 2h in 60 ℃ behind compound that will make like this under the room temperature (560mg, THF(15ml 2mmol)) and 1N sodium hydroxide (5ml) the solution stirring 23h.Use Amber-lite IRC-50(H +-Shi) leach resin behind the neutralization reaction liquid.Filtrate is evaporated to dried and must inscribes and show compound.
Can make following compound with the method that is similar to example 8:
2 '-deoxidation-2 '-vinylidene-5-hydroxymethyluridine
2 '-deoxidation-2 '-the vinylidene thymidine
2 '-deoxidation-2 '-vinylidene-4 '-thio uridine
Example 9
2 '-deoxidation-2 '-the vinylidene guanosine
Step a:
9-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-(ribose-or arabinose-) penta furans-2-(ethynyl) glycosyl] guanine
Topic is shown the compound method 9-[(3 that is same as step a in the example 7,5-O-tetra isopropyl disiloxane-1,3-two bases)-red-penta furyl glycosyl of 2-ketone-β-D-] (2.58g 5mmol) makes guanine.
Step b:
9-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-(vinylidene) and glycosyl] guanine
Topic shows that compound makes with step a gained compound with the method that is same as step b in the example 7.
Step c:
2 '-deoxidation-2 '-the vinylidene guanosine
Topic shows that compound makes with step b gained compound with the method that is same as step c in the example 7.
Also can make following compound with the method that is similar to example 9:
2 '-deoxidation-2 '-vinylidene-4 '-the sulfo-guanosine
The general synthetic method of formula (1b) compound is seen flow process D.
Flow process D
Among the step a, ketone derivatives (2), as 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-is red-penta furans-2-ketone-glycosyl]-2(1H)-pyrimidone can be described by flow process C (the step a) reaction and corresponding 2-ethynyl alcohol (8).As described in flow process C, 2-ethynyl alcohol (8) can exist by two kinds of diastereomers, 4-oxyethyl group-1-[(3 for example, 5-O-tetra isopropyl disiloxane-1,3-two bases)-and β-D-ribose-penta furans-2-(ethynyl) glycosyl]-2(1H)-pyrimidone and 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-arabinose-penta furans-2-(ethynyl) glycosyl]-2(1H)-pyrimidone.
Among the step b, 2-ethynyl alcohol (8) reduction and remove the tetra isopropyl disiloxane protecting group and 2-ethynyl derivatives serving (11).This reduction can be by the known method reductive agent of specialty chemical, and in acid, existence is handled 2-ethynyl alcohol (8) down and carried out as trifluoroacetic acid as triethyl silicane.
At the pyrimidone that adopts the 4-alkoxyl group to replace, the pyrimidone that replaces as the 4-oxyethyl group is during as the initial material (2) of step a, the 4-alkoxyl group can change into the 4-ketone group in the pyrimidone alkali, thereby make corresponding uridine or thymidine derivative (11) and maybe can change into 4-amino, thereby make corresponding cytidine derivatives (11).These reactions are can be by specialty chemical known and finish as method as described in the flow process A.
And, will be appreciated that, 2 '-ethynyl derivatives serving (11) can be used as one of two kinds of diastereomers and exists, i.e. ethynyl 3-hydroxyl one side in being same as the furanose basic ring in one of them, and ethynyl purine or pyrimidyl one side in being same as the furanose basic ring among another.For example, when requiring cytidine derivatives, these geometrical isomers can be called 2 '-deoxidation-2 ' (R)-ethynyl cytidine (glycosyl of or red-penta furans of 4-ketone-1-[β-D--2(R)-(acetylene)]-2(1H)-pyrimidone) and 2 '-deoxidation-2 ' (S)-ethynyl cytidine (glycosyl of or red-penta furans of 4-ketone-1-[β-D--2(S)-(ethynyl)]-2(1H)-pyrimidone.
Know as those skilled in the art, 2 '-(R) of ethynyl derivatives serving (11) and (S) diastereomer can tell with conventional separation method.For example, diastereomer can be resolved with technology according to a conventional method with column chromatography.
Following example has illustrated typical synthetic method shown in the flow process D.Should be understood that these embodiment for illustrative and limit protection scope of the present invention never in any form.
Example 10
2 '-deoxidation-2 ' (R or S) ethynyl cytidine
Step a:
4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-(ribose-or arabinose-) penta furans-2-(ethynyl) glycosyl]-2(1H)-pyrimidone
Topic shows that the compound method for making is same as step a in the example 7.
Step b:
2 '-deoxidation-2 ' (R and S)-ethynyl cytidine
With 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-(ribose-or arabinose-) penta furans-2(ethynyl) glycosyl]-2(1H)-(490mg 0.94mmol) is dissolved under nitrogen atmosphere that (0 ℃) cools off this solution in the methylene dichloride (3ml) and in ice bath to pyrimidone.Add trifluoroacetic acid (0.54ml, 7.08mmol) back with triethyl silicane (0.27ml, 1.71mmol) and under room temperature, stir and spend the night.Reaction mixture washs (2 times, each 5ml) with ethyl acetate (1ml) dilution back with ice-cooled 1N sodium hydroxide solution.With the anhydrous magnesium sulfate drying organic layer and be evaporated to do and 4-oxyethyl group-1-[β-D-red-penta furans-2(R and S)-(ethynyl) glycosyl]-2(1H)-pyrimidone
With the compound that makes like this (885mg, methanol ammonia 3mmol) (10ml, 0 ℃ saturated down) 100 ℃ of heating 2 days in sealed tube.Solution evaporation to dry doubling Dowex 1-X2(OH -Packing is told (R)-and (S)-isomer and is promptly got to inscribe and show compound likes).
Can make following compound with being similar to example 10 described methods:
2 '-deoxidation-2 ' (R or S)-ethynyl-5-methylcytidine
2 '-deoxidation-2 ' (R or S)-ethynyl-5-methylol cytidine
2 '-deoxidation-2 ' (R or S)-ethynyl-4 '-the sulfo-cytidine
(±)-(1 β, 3 α, 4 β)-1-(4-amino-2-hydroxy pyrimidine-6-yl)-2-(α and β)-ethynyl-3-hydroxy-4-hydroxymethyl methylcyclopentane
Example 11
2 '-deoxidation-2 ' (R and S)-ethynyl uridine
Step a:
4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-(ribose-or arabinose-) penta furans-2-(ethynyl) glycosyl]-2(1H)-pyrimidone
Topic shows that the compound method for making is same as step a in the example 7
Step b:
2 '-deoxidation-2 ' (R and S)-ethynyl uridine
4-oxyethyl group-1-[β-D-is red-penta furans-2(R and S)-(ethynyl) glycosyl]-2(1H)-the pyrimidone method for making is same as step b in the example 10.
Stir 2h down in 60 ℃ behind compound (590mg, THF(15ml 2mmol)) that stirring makes like this under the room temperature and 1N sodium hydroxide (5ml) the solution 23h.With Amber lite IRC-50(H +-Shi) leach resin behind the neutralization reaction liquid.Filtrate is evaporated to dry doubling Dowex 1-X2(OH -The chromatographic column of Tian Chonging is told (R)-and (S)-isomer and must be inscribed and show compound likes).
Can make following compound with the method that is similar to example 11:
2 '-deoxidation-2 ' (R and S)-ethynyl-5-hydroxymethyluridine
2 '-deoxidation-2 ' (R and S)-ethynyl thymidine
2 '-deoxidation-2 ' (R and S)-ethynyl-4 '-thio uridine.
Example 12
2 '-deoxidation-2 ' (R and S)-ethynyl guanosine
Step a:
9-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-(ribose-or arabinose-) penta furans-2-(ethynyl) glycosyl] guanine
Topic shows that compound is to be same as the method 9-[(3 of step a in the example 7,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-(ribose-or arabinose-) penta furans-2-(ethynyl) glycosyl] (2.58g 5mmol) makes guanine.
Step b:
2 '-deoxidation-2 ' (R and S)-ethynyl guanosine
Topic shows that compound use a) middle gained compound to make with the method that is same as step b in the example 10.
Can make following compound with the method that is similar to example 9:
2 '-deoxidation-2 ' (R and S)-ethynyl-4 '-the sulfo-guanosine
2 '-deoxidation-2 ' (R and S)-8-nitrogen guanosine
2 '-deoxidation-2 ' (R and S)-N-methylguanosine
2 '-deoxidation-2 ' (R and S)-8-chlorine guanosine
In above-mentioned many examples, adopt 4-oxyethyl group-pyrimidone derivatives as original material (2).Known to those skilled in the art, the 4-oxyethyl group can change into ketone group (to form uridine/thymidine derivative) or amino (to form cytidine) in case of necessity.On the other hand, require uridine, when thymidine or cytidine derivatives, base is cytosine(Cyt), uridylic or thymus pyrimidine in the initial material of used 2-ketone (2).
The initial material that is used for the described general synthetic method of flow process A-D is easy to adopt the known synthetic method of this professional people to make.For example, 4-oxyethyl group-1-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-red-penta furyl of 2-ketone-β-D-]-2(1H)-pyrimidone can be used as formula (1), the original material of chemical compound lot (1a) and (1b), and available uridine is pressed Matsuda et al.[Chem.Pharm.Bull.1988,36,945] described method makes.Can be by being similar to Hansske et al.[Tetrahedron1984,40,125] described method makes 9-[(3,5-O-tetra isopropyl disiloxane-1,3-two bases)-β-D-(ribose-or arabinose-) penta furans-2-(ethynyl) glycosyl] guanine.The initial material of other 2-ketone can be with being similar to above-mentioned method and having seen Hansske and Robins[Tetrahedron Lett.1983,24,1589] described similar approach makes.
In another embodiment, the present invention proposes the tumour patient methods of treatment, wherein takes the formula (1) of effective therapeutic dose, (1a) or antineoplastic compound (1b).Used " tumour patient " is the morbid state of quick growth of phalangeal cell or tumour.Available especially formula (1), (1a) or (1b) the tumour morbid state of compounds for treating comprises: leukemia, as, but be not limited only to acute lymphocytoblast, chronic lymphocytic, acute myloblastic and chronic mylocy-tic; Acinous carcinoma, as, but be not limited only to neck, oesophagus, stomach, the acinous carcinoma of intestines and lung; Sarcoma, as, but be not limited only to oesteroma, osteosarcoma, lepoma, liposarcoma, vascular tumor and meat pipe sarcoma; Melanoma comprises non-melanistic and melanistic; And the mixed type tumour, as, but be not limited in sarcocarcinoma, lymphoid tissue-type, folicullar reticulum, cell sarcoma and Hokdkin disease.Neoplastic disease treatment is with special preferred formula (1), and (1a) or (1b) compound comprises:
2 '-deoxidation-2 '-the difluoro methylene cytidine
2 '-deoxidation-2 '-the difluoro methylene uridine
2 '-deoxidation-2 '-the difluoro methylene guanosine
(Z) and (E)-2 '-deoxidation-2 '-fluoro methylene radical cytidine
(Z) and (E)-2 '-deoxidation-2 '-fluoro methylene radical uridine
(Z) and (E)-2 '-deoxidation-2 '-fluoro methylene radical guanosine
2 '-deoxidation-2 '-the vinylidene cytidine
2 '-deoxidation-2 '-the vinylidene uridine
2 '-deoxidation-2 '-the vinylidene guanosine
2 '-deoxidation-2 ' (R and S)-ethynyl cytidine
2 '-deoxidation-2 ' (R and S)-ethynyl uridine
2 '-deoxidation-2 ' (R and S)-ethynyl guanosine
Used " patient " refers to suffer from the warm-blooded animal of specific tumors or virus disease, as the mankind.
Used " effectively therapeutic dose " formula (1), (1a) and (1b) antineoplastic compound life-span of referring to can to control growth of tumor effectively after the single or multiple doses of patient is taken or prolonging patient surpasses the significant quantity when not carrying out this treatment.Used " control tumor growth " refers to slow down, and interrupts, and prevents or stops its growth and transfer, needn't refer to eradicate fully tumour certainly.
In addition, the present invention proposes to treat virus infection patient's method, comprising effective therapeutic dose formula (1), (1a) and antiviral compound (1b).Used " virus infection " refers to up-set condition or situation, and characteristics are cytopathies, virus replication and hyperplasia.Formula (1), (1a) or (1b) virus infection that can especially effectively treat of compound comprises: Retro virus, as, but and only limit to HTLV-I, HTLV-II; Human immunodeficiency virus, HTLV-III (AIDS virus) etc.; RNA viruses, as, but be not limited in influenza type A, B and C, mumps, measles, rhinovirus, dengue virus, rubella virus, rabies virus, hepatitis virus A, encephalitis etc.; Dna virus, as, but be not limited to simplexvirus, cowpox blister virus, pappiloma virus (wart), hepatitis virus B etc.
Used " effectively therapeutic dose " formula (1), (1a) or the life-span that refers to can to control the growth of virus effectively after the single or multiple doses of patient is taken or prolong patient of antiviral compound (1b) surpass significant quantity when not carrying out this treatment.Used " control viral growth " refers to slow down, and interrupts, and prevents or stops its growth and transfer, needn't refer to eradicate fully virus certainly.
Used " effectively therapeutic dose " refers to formula (1), (1a) or (1b) the antitumor or antiviral amount of effective treatment of compound.Know as the present technique field, the clinical diagnosis doctor can adopt common technique and observe the result who obtains under the analogue and just can easily measure effective therapeutic dose.When measuring effective therapeutic dose or dosage, the clinical diagnosis doctor will consider quantity of parameters, comprising, but be not limited in: mammal species, its size, age and total healthy state; The concrete state of an illness; Ill degree or severity; Each patient's reaction; The particular compound of taking; Medicining mode; The Bioabsorbable of institute's formulation; Selected formulation; The companion uses therapy; And other relevant environment.
Effective therapeutic dose formula (1), (1a) or (1b) compound can be extremely about 100mh/kg/day of about 0.1mg/kg body weight/day (mg/kg/day).Preferred amounts is about 0.5 to about 10mg/kg/day.
When above-mentioned patient is treated, formula (1), (1a) or (1b) compound can any formulation be taken, and this can make this mixture be able to carry out bio-absorbable by significant quantity, comprises oral and the parenteral medication.For example, formula (1), (1a) or (1b) compound can be oral, subcutaneous administration, muscle administration, intravenously administrable, percutaneous drug delivery, intranasal administration and rectal administration etc.Most preferably be oral.Those skilled in the art are easy to choose suitable formulation and take mode when filling a prescription, this depends on the characteristic of selected compounds, treatment case, the relevant situation with other of the state of an illness.
This compound can become pharmaceutical composition to take separately or with pharmaceutical carrier or vehicle, and the ratio of carrier or vehicle and character can be according to selected compounds solvability and chemical propertys, instructions of taking, and standard drug practice and determining.The compounds of this invention, although itself is effectively, also can its medicinal acid addition salt preparation and take, reaching stability, crystallization is convenient and improve purpose such as solubleness.
In another embodiment, the present invention proposes composition, comprising formula (1), (1a) or (1b) compound be mixed state or with one or more inert support couplings.These compositions for example can be used as standard of perfection, convenient large quantities of shipping or as pharmaceutical composition.Formula (1), but (1a) or (1b) identification number of compound is to be easy to the amount that can survey with this professional known standard test methods.Formula (1), but (1a) or (1b) identification number of compound is generally about 0.001%w of composition to about 75%w.Carrier can be non-degradable or with formula (1), (1a) or (1b) carry out any material of covalent reaction.Suitable inert support is a water; Aqueous buffer solution, as be used for the aqueous buffer solution that high performance liquid chromatography (HPLC) is analyzed; Organic solvent, as acetonitrile, ethyl acetate and hexane etc.; And pharmaceutical carrier or vehicle.
More particularly, the present invention proposes pharmaceutical composition, comprising effective therapeutic dose formula (1), (1a) or (1b) compound, be mixed state or with one or more pharmaceutical carriers or vehicle coupling.
The method that pharmaceutical composition is known with pharmaceutical industry makes.Carrier or vehicle can be solid, and semi-solid state or fluent meterial can be used as the carrier or the media of activeconstituents.Suitable carriers and vehicle are known in this specialty.This pharmaceutical composition is suitable for oral or parenteral is taken, for example can be in the form of sheets, and capsule, suppository, solution and suspension etc.
The compounds of this invention can be for example with inert diluent or oral with edible carrier.Can be encapsulated in the gelatine capsule it or tablet forming.In order to make medicinal preparation for oral administration, this compound can with vehicle and with and make sheet, lozenge, capsule, elixir, suspension, syrup, wafer and chewing gum etc.These preparations should contain at least 4% The compounds of this invention activeconstituents, but this depends on concrete formulation, can reach 4% to about 70% of unit weight easily.The The compounds of this invention amount should guarantee to reach proper dosage in the composition.Oral dosage unit form contains 5.0～300mg The compounds of this invention in preferred composition of the present invention and the preparation.
Tablet, pill also can contain one or more adjutants in capsule and the lozenge: tackiness agent, as Microcrystalline Cellulose, tragakanta or gelatin; Vehicle is as starch or lactose; Decomposition agent, as alginic acid, Primogel and W-Gum etc.; Lubricant is as Magnesium Stearate or Sterotex; Glidant is as colloidal silica; And can add sweetener, as sucrose or asccharin or spices, as thin He, wintergreen oil or tangerine essence.When dosage unit forms is capsule, wherein can contain the liquid carrier except that above-mentioned substance, as polyoxyethylene glycol or fatty oil.Other dosage unit forms can contain can improve the dose unit profile, as carries out other various materials of dressing.Therefore, tablet or pill can be with sugared, and shellac or other enteric coating Drug coating coat.In the syrup except that The compounds of this invention and, also can contain sucrose as sweetener and some sanitas, stain and pigment and spices.The material that is used to produce this based composition reaches medicinal purity and nontoxic the amount ranges planted agent.
For reaching parenteral medication purpose, The compounds of this invention can be made into solution suspension.These preparations should contain the present invention of at least 0.1%, but can be 0.1 of its weight～about 50%.The The compounds of this invention consumption should guarantee to reach proper dosage in these compositions.Parenteral dosage units contains 5.0～100mg The compounds of this invention in preferred composition of the present invention and the preparation.
Solution or suspension also can contain one or more following adjutants: sterile diluent, and as injection water, salts solution, solidity oil, polyoxyethylene glycol, glycerine, propylene glycol or other synthetic; Antiseptic-germicide is as xitix or sodium pyrosulfate; Sequestrant is as ethylene diaminetetraacetic acid; Delay and put agent, as acetate, Citrate trianion or phosphoric acid salt and nervous conditioning agent are as sodium-chlor or glucose.Parenteral administration can be enclosed in ampoule, handles in syringe or glass or the plastic jar.
As for structurally associated compound with special purpose, to formula (1), (1a) or (1b) compound, some group and configuration are particular preferred in its end-use.
Speak of substituent X 1And X 2, X in the formula (1) 1Be fluorine, and X 2Be hydrogen, and X 1Be hydrogen, and X 2For the compound of fluorine in general just preferred especially.
Also have substituent R, formula (1a) and (1b) middle R be hydrogen compound is in general preferred especially.
Below be formula (1), (1a) or (1b) other preferred embodiment of compound: V is the compound of oxo, Y 1Be the compound of CH base, Y 2Be nitrogen compound, Y 3For nitrogen compound and Z are that the compound of hydrogen is in general particular preferred.
Following table is listed the formula (1) in particularly preferred embodiment of the present invention, (1a) or (1b) compound:
2 '-deoxidation-2 '-difluoro methylene-cytidine
2 '-deoxidation-2 '-difluoro methylene-uridine
2 '-deoxidation-2 '-difluoro methylene-guanosine
(Z) and (E) 2 '-deoxidation-2 '-fluoro methylene radical-cytidine
(Z) and (E) 2 '-deoxidation-2 '-fluoro methylene radical-uridine
(Z) and (E) 2 '-deoxidation-2 '-fluoro methylene radical-guanosine
2 '-deoxidation-2 '-vinylidene-cytidine
2 '-deoxidation-2 '-vinylidene-uridine
2 '-deoxidation-2 '-vinylidene-guanosine
2 '-deoxidation-2 ' (R) and (S)-ethynyl-cytidine
2 '-deoxidation-2 ' (R) and (S)-ethynyl-uridine
2 '-deoxidation-2 ' (R) and (S)-ethynyl-guanosine
The above-mentioned particularly preferred embodiment of the present invention of only schematically having listed should be understood that this also can limit protection scope of the present invention by any way.

Claims (1)

1, following formula: compound method for making
Wherein
V is an oxygen, methylene radical or sulphur,
X 1And X 2One of be halogen, and another is a hydrogen,
B is the following formula group
Figure 891085572_IMG2
Y wherein 1Be the CH base; Y 2And Y 3Represent nitrogen independently; Y 4Be hydrogen; Y 5Be amino; And Z is NH 2
This method step comprises
A) with 3,5-O-tetra isopropyl disiloxane-1, reactant salt in 3-two bases-2-ketone one nucleoside derivates and the aryl sulfonic acid groups halogenated methylene phosphorus and 3,5-O-tetra isopropyl disiloxane-1,3-two bases-2-aryl sulfonyl halogenated methylene-nucleoside derivates,
B is with gained compound in a) and fluorine anion or acid-respons and must corresponding 2-arylsulfonyl halo methylene radical-nucleoside derivates,
C) with b) in gained compound and aluminium/amalgam, sodium/amalgam, or the two isobutyl-nitriles reaction carrying out of tri-butyl tin hydride/azo acidic aqueous solution processing and
D) in case of necessity with 2-aryl sulfonyl halogenated methylene-nucleoside derivates and alkali reaction.
CN89108557A 1988-11-15 1989-11-15 Novel 2'-halomethylidene, uridine and guanosine drivatives Expired - Fee Related CN1022248C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27147988A 1988-11-15 1988-11-15
US271,479 1988-11-15

Publications (2)

Publication Number Publication Date
CN1042715A CN1042715A (en) 1990-06-06
CN1022248C true CN1022248C (en) 1993-09-29

Family

ID=23035764

Family Applications (1)

Application Number Title Priority Date Filing Date
CN89108557A Expired - Fee Related CN1022248C (en) 1988-11-15 1989-11-15 Novel 2'-halomethylidene, uridine and guanosine drivatives

Country Status (19)

Country Link
EP (1) EP0372268B1 (en)
JP (1) JP2802947B2 (en)
KR (1) KR0144865B1 (en)
CN (1) CN1022248C (en)
AR (1) AR247891A1 (en)
AT (1) ATE105297T1 (en)
AU (1) AU621160B2 (en)
CA (1) CA2002648C (en)
DE (1) DE68915128T2 (en)
DK (1) DK171844B1 (en)
ES (1) ES2056180T3 (en)
FI (1) FI92588C (en)
HU (3) HU205134B (en)
IE (1) IE63563B1 (en)
IL (1) IL92293A (en)
NO (1) NO172240C (en)
NZ (1) NZ231365A (en)
PT (1) PT92309B (en)
ZA (1) ZA898567B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
WO1988007049A1 (en) * 1987-03-19 1988-09-22 Yamasa Shoyu Kabushiki Kaisha 2'-alkylidenepyrimidine nucleoside derivatives, process for their preparation, and their use
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
US5521163A (en) * 1990-07-13 1996-05-28 University Of Birmingham Antiviral pyrimidine nucleosides and methods for using same
FR2668153B1 (en) * 1990-10-22 1995-03-31 Pasteur Merieux Serums Vacc NOVEL RIBONUCLEOSIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM.
WO1993022327A1 (en) * 1992-04-23 1993-11-11 Yoshitomi Pharmaceutical Industries, Ltd. 2'-methylidenenucleoside compound and pharmaceutical use thereof
US5589587A (en) * 1992-05-12 1996-12-31 Merrell Pharmaceuticals Inc. Process for the preparation of ribonucleotide reductase inhibitors
CA2133961C (en) * 1992-05-12 1998-03-31 James R. Mccarthy A process for the preparation of ribonucleotide reductase inhibitors
CA2150671C (en) * 1992-12-03 2000-12-26 Sai P. Sunkara Compositions containing acyclovir-like compounds and 2'-vinyl substituted nucleoside analogs for the treatment of viral infections
CN1043231C (en) * 1994-01-07 1999-05-05 默里尔药物公司 (E)-α-Deoxy-α-(fluoromethylene)cytidine monohydrate
US5627053A (en) * 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
WO1996001638A1 (en) * 1994-07-11 1996-01-25 Hoechst Marion Roussel, Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
EP0770621A4 (en) * 1994-07-12 1998-01-28 Yamasa Corp 2'-DESOXY-2 '- (METHYLIDENE SUBSTITUTED OR NON-SUBSTITUTED) -4'-THIONUCLEOSIDE
US20040006002A1 (en) * 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
JP2005522443A (en) * 2002-02-14 2005-07-28 フアーマセツト・リミテツド Modified fluorinated nucleoside analogues
KR20040036417A (en) * 2002-10-25 2004-04-30 정낙신 Thionucleoside derivatives having potent anti-cancer activity and the pharmaceutical compositions containing the same
CN100389119C (en) * 2004-10-27 2008-05-21 北京东华康明生物科技有限公司 (trans)-2-deoxy-2-(fluoromethano)-4-R acyl-cytidine compound, preparation process and use thereof
GEP20166496B (en) 2011-12-22 2016-06-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2013344757A1 (en) * 2012-11-19 2015-05-21 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
WO2018092107A1 (en) * 2016-11-21 2018-05-24 Munisekhar Medasani Novel anti-viral and anti-cancer molecule

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007049A1 (en) * 1987-03-19 1988-09-22 Yamasa Shoyu Kabushiki Kaisha 2'-alkylidenepyrimidine nucleoside derivatives, process for their preparation, and their use

Also Published As

Publication number Publication date
PT92309B (en) 1996-06-28
JP2802947B2 (en) 1998-09-24
ZA898567B (en) 1990-08-29
AU4461189A (en) 1990-05-24
IL92293A0 (en) 1990-07-26
IE893651L (en) 1990-05-15
DK171844B1 (en) 1997-06-30
PT92309A (en) 1990-05-31
DE68915128D1 (en) 1994-06-09
DE68915128T2 (en) 1994-08-25
NO172240C (en) 1993-06-23
AU621160B2 (en) 1992-03-05
KR0144865B1 (en) 1998-07-01
NO894539D0 (en) 1989-11-14
CN1042715A (en) 1990-06-06
AR247891A1 (en) 1995-04-28
EP0372268A1 (en) 1990-06-13
HU00045A9 (en) 1995-01-30
FI895417A0 (en) 1989-11-14
HU895900D0 (en) 1990-02-28
HU210343A9 (en) 1995-03-28
FI92588B (en) 1994-08-31
JPH02178272A (en) 1990-07-11
IL92293A (en) 1995-01-24
NO172240B (en) 1993-03-15
NZ231365A (en) 1992-08-26
CA2002648C (en) 2000-02-29
KR900007833A (en) 1990-06-02
HUT51642A (en) 1990-05-28
ATE105297T1 (en) 1994-05-15
ES2056180T3 (en) 1994-10-01
HU205134B (en) 1992-03-30
NO894539L (en) 1990-05-16
FI92588C (en) 1994-12-12
DK570089D0 (en) 1989-11-14
EP0372268B1 (en) 1994-05-04
CA2002648A1 (en) 1990-05-15
DK570089A (en) 1990-05-16
IE63563B1 (en) 1995-05-17

Similar Documents

Publication Publication Date Title
CN1022248C (en) Novel 2'-halomethylidene, uridine and guanosine drivatives
CN1020194C (en) Process for preparation of difluoronucleoside derivatives
CN100347185C (en) Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
CN1035617C (en) N-oxycarbonyl substituted 5′-deoxy-5-fluorocytidine derivatives
CN1029970C (en) Pyrrolopyrimidine derivatives
CN1040761C (en) Containing fused nitrogen-containing heterocyclic derivatives containing ethyl phosphonate side chains, pharmaceutical compositions containing them and applications thereof
CN1151167C (en) Purine derivatives
CN1279686A (en) Inhibitors of nucleoside metabolism
CN87108265A (en) antiviral compound
CN1100728A (en) Nucleosides and oligonucleotides having 2'-ether groups
CN1436082A (en) 3'- or 2'-hydroxymethyl substituted nucleoside derivatives for the treatment of hepatitis virus infection
HK1043940A1 (en) 1,3-oxathiolane nucleoside analoques
CN1871250A (en) Nucleoside compounds for the treatment of viral infections
CN1346360A (en) (1R, cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1-methanol phosphoramidate and mono-, di- and tri-phosphates as antiviral agents
CN1040032A (en) New alpha-glucosidase inhibitors
CN1023804C (en) Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives
CN1023561C (en) Process for preparing cryptoclindamycin/adenosine derivatives
CN1091742A (en) Water soluble camptothecin derivatives
CN1017153B (en) Preparation method of purine-substituted oxetane compound
CN1201037A (en) 5'-deoxy-cytidine derivatives
CN1027373C (en) Therapeutic nucleosides
CN1684970A (en) (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof
CN1533397A (en) 6-2' - (phosphonomethoxy) alkoxypyrimidine derivatives having antiviral activity
CN1046334A (en) New 2 '-halogenated methylene, 2 '-vinylidene and 2 '-the ethynyl adenosine derivative
CN1084178A (en) 2 of the antiviral and antitumour activity of tool '-deoxidation-2 ', 2 '-difluoro (2,6,8-replaces) purine nucleoside and intermediate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: MERRELL PHARMACEUTICALS INC.

Free format text: FORMER NAME OR ADDRESS: MERRELL DOW PHARMACEUTICALS INC.

CP01 Change in the name or title of a patent holder

Patentee after: Merrell Dow Pharmaceuticals Inc.

Patentee before: Merrell Dow Pharmaceuticals Ltd.

C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee